|
US7981420B2
(en)
|
2000-12-22 |
2011-07-19 |
Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. |
Therapeutic use of antibodies directed against repulsive guidance molecule (RGM)
|
|
EP1928905B1
(de)
|
2005-09-30 |
2015-04-15 |
AbbVie Deutschland GmbH & Co KG |
Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
|
|
FR2892724B1
(fr)
*
|
2005-11-02 |
2008-01-04 |
Lab Francais Du Fractionnement |
Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
|
|
US9896511B2
(en)
|
2007-01-10 |
2018-02-20 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
|
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
US20110229471A1
(en)
|
2008-11-26 |
2011-09-22 |
Cedars-Sinai Medical Center |
Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
|
|
JP5781514B2
(ja)
*
|
2009-09-06 |
2015-09-24 |
プロトエービー リミテッド |
Hsp65由来のペプチド6に特異的なヒト化抗体、その方法及び使用
|
|
MX2012006560A
(es)
|
2009-12-08 |
2012-10-05 |
Abbott Gmbh & Co Kg |
Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
|
|
PH12012502193A1
(en)
|
2010-05-06 |
2021-08-09 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
|
|
EP2566892B1
(en)
|
2010-05-06 |
2017-12-20 |
Novartis AG |
Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
|
|
WO2012009705A1
(en)
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Ang-2 binding complexes and uses thereof
|
|
US8766034B2
(en)
|
2010-09-22 |
2014-07-01 |
Cedars-Sinai Medical Center |
TL1A model of inflammation fibrosis and autoimmunity
|
|
JO3375B1
(ar)
|
2010-11-08 |
2019-03-13 |
Regeneron Pharma |
أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
|
|
EP3604339B1
(en)
|
2011-01-14 |
2021-03-10 |
The Regents Of The University Of California |
Therapeutic antibodies against ror-1 protein and methods for use of same
|
|
JP2014511174A
(ja)
|
2011-02-07 |
2014-05-15 |
ネオトープ バイオサイエンシーズ リミテッド |
Apoe免疫療法
|
|
EP2673297A2
(en)
|
2011-02-11 |
2013-12-18 |
Zyngenia, Inc. |
Monovalent and multivalent multispecific complexes and uses thereof
|
|
WO2012161856A1
(en)
*
|
2011-05-20 |
2012-11-29 |
Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services |
Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
|
|
EP2714738B1
(en)
|
2011-05-24 |
2018-10-10 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
|
SG11201400916XA
(en)
|
2011-08-22 |
2014-06-27 |
Cangene Corp |
Clostridium difficile antibodies
|
|
KR101982899B1
(ko)
|
2011-09-30 |
2019-05-27 |
테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 |
TL1a에 대한 항체 및 그의 용도
|
|
ES2666856T3
(es)
|
2011-11-04 |
2018-05-08 |
Novartis Ag |
Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media
|
|
EP3369746A1
(en)
|
2012-01-27 |
2018-09-05 |
AbbVie Deutschland GmbH & Co KG |
Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
|
|
TWI595007B
(zh)
|
2012-09-10 |
2017-08-11 |
Neotope Biosciences Ltd |
抗mcam抗體及相關使用方法
|
|
WO2014055967A2
(en)
*
|
2012-10-05 |
2014-04-10 |
Neotope Biosciences Limited |
Compositions and methods for treating diseases of protein aggregation involving ic3b deposition
|
|
WO2014106602A1
(en)
*
|
2013-01-02 |
2014-07-10 |
Glenmark Pharmaceuticals S.A. |
Antibodies that bind to tl1a and their uses
|
|
US10501531B2
(en)
|
2013-03-13 |
2019-12-10 |
Prothena Biosciences Limited |
Tau immunotherapy
|
|
KR20230109779A
(ko)
|
2013-03-27 |
2023-07-20 |
세다르스-신나이 메디칼 센터 |
Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전
|
|
KR102042174B1
(ko)
|
2013-03-29 |
2019-11-08 |
삼성전자주식회사 |
인간화 및 친화도 성숙된 항 c-Met 항체 및 그의 용도
|
|
EP3022295A4
(en)
|
2013-07-19 |
2017-03-01 |
Cedars-Sinai Medical Center |
Signature of tl1a (tnfsf15) signaling pathway
|
|
TWI636065B
(zh)
*
|
2013-08-05 |
2018-09-21 |
伊瑪提克斯生物科技有限公司 |
新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物
|
|
US20160264684A1
(en)
*
|
2013-10-10 |
2016-09-15 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
US9683998B2
(en)
*
|
2013-11-13 |
2017-06-20 |
Pfizer Inc. |
Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
|
|
JP2017514458A
(ja)
|
2014-03-12 |
2017-06-08 |
プロセナ バイオサイエンシーズ リミテッド |
Lg4−5に対して特異的な抗−ラミニン4抗体
|
|
PT3116911T
(pt)
|
2014-03-12 |
2019-09-04 |
Prothena Biosciences Ltd |
Anticorpos anti-mcam e métodos de utilização associados
|
|
US10160805B2
(en)
|
2014-07-11 |
2018-12-25 |
New York University |
Methods of treating inflammatory bowel disease by administering tumor necrosis factor-like ligand 1A or an agonistic death-domain receptor 3 antibody
|
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
FI3218005T3
(fi)
|
2014-11-12 |
2023-03-31 |
Seagen Inc |
Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä
|
|
DK3270965T3
(da)
|
2015-03-18 |
2020-06-08 |
Seattle Genetics Inc |
Cd48-antistoffer og konjugater deraf
|
|
US20170021020A1
(en)
|
2015-07-23 |
2017-01-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Monoclonal antibody and vaccine targeting filamentous bacteriophage
|
|
TWI703158B
(zh)
|
2015-09-18 |
2020-09-01 |
美商希佛隆公司 |
特異性結合tl1a之抗體
|
|
BR112018006237A2
(pt)
|
2015-09-29 |
2018-10-09 |
Celgene Corp |
proteínas de ligação a pd-1 e métodos de uso das mesmas
|
|
US20180319889A1
(en)
*
|
2015-11-02 |
2018-11-08 |
La Jolla Institute For Allergy & Immunology |
Method and medicament for treating airway and/or lung diseases
|
|
CA3002097A1
(en)
|
2015-11-12 |
2017-05-18 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
CR20180365A
(es)
|
2015-12-16 |
2018-09-28 |
Amgen Inc |
PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
|
|
KR20240095481A
(ko)
|
2016-03-17 |
2024-06-25 |
세다르스-신나이 메디칼 센터 |
Rnaset2를 통한 염증성 장 질환의 진단 방법
|
|
EP3436480A4
(en)
|
2016-03-30 |
2019-11-27 |
Musc Foundation for Research Development |
METHOD FOR THE TREATMENT AND DIAGNOSIS OF CANCER BY TARGETING GLYCOPROTEIN A REPETITION PREDOMINANT (GARP) AND FOR EFFECTIVE IMMUNOTHERAPY ALONE OR IN COMBINATION
|
|
PT3452507T
(pt)
|
2016-05-02 |
2022-12-20 |
Prothena Biosciences Ltd |
Imunoterapia anti-tau
|
|
MX2018013386A
(es)
|
2016-05-02 |
2019-02-28 |
Prothena Biosciences Ltd |
Anticuerpos que reconocen tau.
|
|
MY198194A
(en)
|
2016-05-02 |
2023-08-09 |
Prothena Biosciences Ltd |
Antibodies Recognizing Tau
|
|
MX392069B
(es)
*
|
2016-05-09 |
2025-03-21 |
Bristol Myers Squibb Co |
Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
|
|
EP3458466B1
(en)
|
2016-05-20 |
2024-08-07 |
Cedars-Sinai Medical Center |
Diagnosis of inflammatory bowel disease based on genes
|
|
RU2630647C1
(ru)
*
|
2016-05-27 |
2017-09-11 |
Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства |
ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА
|
|
JP2019534859A
(ja)
*
|
2016-09-19 |
2019-12-05 |
セルジーン コーポレイション |
Pd−1結合タンパク質を使用して白斑を治療する方法
|
|
MX2019002867A
(es)
|
2016-09-19 |
2019-11-12 |
Celgene Corp |
Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1.
|
|
KR20190082815A
(ko)
*
|
2016-10-26 |
2019-07-10 |
세다르스-신나이 메디칼 센터 |
중화 항-tl1a 단일 클론 항체
|
|
WO2018094143A1
(en)
|
2016-11-17 |
2018-05-24 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
WO2018160909A1
(en)
|
2017-03-03 |
2018-09-07 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
SG11201909708VA
(en)
*
|
2017-04-21 |
2019-11-28 |
Mellitus Llc |
Methods and antibodies for diabetes-related applications
|
|
KR102784294B1
(ko)
|
2017-05-02 |
2025-03-19 |
프로테나 바이오사이언시즈 리미티드 |
타우 인식 항체
|
|
CN111201030B
(zh)
|
2017-07-25 |
2024-11-01 |
真和制药有限公司 |
通过阻断tim-3和其配体的相互作用治疗癌症
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
CN112585165B8
(zh)
*
|
2018-04-25 |
2025-02-14 |
普罗米修斯生物科学公司 |
优化的抗tl1a抗体
|
|
RU2687609C1
(ru)
*
|
2018-05-30 |
2019-05-15 |
Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства |
Гуманизированное антитело к конформационному эпитопу сз компонента комплемента человека
|
|
CA3105448A1
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
WO2020160156A2
(en)
|
2019-01-30 |
2020-08-06 |
Immutics, Inc. |
Anti-gal3 antibodies and uses thereof
|
|
GB2599228B
(en)
|
2019-02-21 |
2024-02-07 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
CN119039441A
(zh)
|
2019-02-21 |
2024-11-29 |
马伦戈治疗公司 |
与nkp30结合的抗体分子及其用途
|
|
JP7630834B2
(ja)
|
2019-03-03 |
2025-02-18 |
プロセナ バイオサイエンシーズ リミテッド |
タウ認識抗体
|
|
NZ787680A
(en)
|
2019-10-24 |
2026-02-27 |
Cedars Sinai Medical Center |
Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
|
|
AU2020416273A1
(en)
|
2020-01-03 |
2022-07-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
BR112022013892A2
(pt)
*
|
2020-01-13 |
2022-10-04 |
Truebinding Inc |
Anticorpos anti-gal3 e métodos de uso
|
|
WO2021202798A1
(en)
*
|
2020-04-02 |
2021-10-07 |
The United States Of America As Represented By The Secretary Of The Navy |
Antigen binding proteins to class 5 etec adhesins
|
|
EP4157338A4
(en)
|
2020-05-26 |
2024-11-13 |
TrueBinding, Inc. |
METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
|
|
WO2023141297A2
(en)
*
|
2022-01-21 |
2023-07-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules comprising g6b binder and/or cd34 binder and uses thereof
|
|
AU2024273758A1
(en)
|
2023-05-17 |
2025-12-04 |
Genentech, Inc. |
Anti-tl1a antibody therapeutic methods
|
|
CN120399074B
(zh)
*
|
2023-06-02 |
2025-12-30 |
安徽金百奥生物科技有限公司 |
一种与人dr3胞外域高亲和力的纳米抗体
|
|
CN121843714A
(zh)
|
2023-08-11 |
2026-04-10 |
派拉冈医疗公司 |
Tl1a结合抗体及使用方法
|
|
CN120530139A
(zh)
*
|
2023-12-29 |
2025-08-22 |
成都优洛生物科技有限公司 |
抗tl1a抗体或其抗原结合片段及应用
|
|
CN120424214A
(zh)
*
|
2024-02-05 |
2025-08-05 |
三生国健药业(上海)股份有限公司 |
一种抗tl1a抗体及其制备方法和用途
|
|
WO2025212534A1
(en)
*
|
2024-04-05 |
2025-10-09 |
Board Of Regents, The University Of Texas System |
Monoclonal antibodies neutralizing marburg and ravn virus
|
|
CN119552252B
(zh)
*
|
2025-01-16 |
2025-11-25 |
华润生物医药有限公司 |
抗tl1a抗体及其制备方法和应用
|
|
CN120699151A
(zh)
*
|
2025-06-26 |
2025-09-26 |
国科大杭州高等研究院 |
一种tl1a抗体及其制备方法与应用
|